Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor

Biosensors

Po-Yuan Lin²  Kai-Lun Cheng⁵  James D. McGuffin-Cawley²  Fuh-Sheng Shieu⁵  Anna C. Samia³  Sanjay Gupta⁶  Matthew Cooney¹  Cheryl L. Thompson⁴ 

[1] Division of Hematology/Oncology, University Hospital Case Medical Center, 10900 Euclid Avenue, Cleveland, OH 44106, USA; E-Mail:;Department of Materials Science & Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA; E-Mails:;Department of Chemistry, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA; E-Mail:;Department of Family Medicine, University Hospital Case Medical Center, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA; E-Mail:;Department of Materials Science & Engineering, National Chung Hsing University, No. 250, Guoguang Road, Nan District, Taichung City 402, Taiwan; E-Mails:;Department of Urology, University Hospital Case Medical Center, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA; E-Mail:

关键词: alpha-methylacyl-CoA racemase (AMACR);    prostate cancer;    biosensor;    electrochemical;    nanoparticles;   

DOI  :  10.3390/bios2040377

来源: mdpi

【 摘 要 】

Although still commonly used in clinical practice to screen and diagnose prostate cancer, there are numerous weaknesses of prostate-specific antigen (PSA) testing, including lack of specificity and the inability to distinguish between aggressive and indolent cancers. A promising prostate cancer biomarker, alpha-methylacyl-CoA racemase (AMACR), has been previously demonstrated to distinguish cancer from healthy and benign prostate cells with high sensitivity and specificity. However, no accurate clinically useful assay has been developed. This study reports the development of a single use, disposable biosensor for AMACR detection. Human blood samples were used to verify its validity, reproducibility and reliability. Plasma samples from 9 healthy males, 10 patients with high grade prostatic intraepithelial neoplasia (HGPIN), and 5 prostate cancer patients were measured for AMACR levels. The average AMACR levels in the prostate cancer patients was 10 fold higher (mean(SD) = 0.077 (0.10)) than either the controls (mean(SD) = 0.005 (0.001)) or HGPIN patients (mean(SD) = 0.004 (0.0005)). At a cutoff of between 0.08 and 0.9, we are able to achieve 100% accuracy in separating prostate cancer patients from controls. Our results provide strong evidence demonstrating that this biosensor can perform as a reliable assay for prostate cancer detection and diagnosis.

【 授权许可】

CC BY   
© 2012 by the authors; licensee MDPI, Basel, Switzerland.